What stands out
- Fixed active concentrations
- Full prescribing information
What to weigh
- Not indicated for maintenance; the label has important population and use limits.
The medicine is not a telehealth membership
TRI-LUMA is marketed by Galderma and prescribed through a healthcare professional. The drug label identifies fluocinolone acetonide 0.01%, hydroquinone 4% and tretinoin 0.05%.[source]
A pharmacy purchase should therefore be considered separately from the consultation used to obtain the prescription. Our brand review focuses on this medicine rather than implying that Galderma supplies the same care model as an online clinic.
Its indication is narrower than generic dark-spot marketing
The label concerns short-term treatment of moderate to severe facial melasma alongside sun-avoidance measures, including sunscreen. It is not indicated as continuous maintenance treatment.[source]
That scope is valuable information. It should not be broadened into a promise to treat every type of discoloration, every body site or every skin tone with equal evidence.
Read the studied population and warnings
The labeling says safety and efficacy were not studied in Fitzpatrick skin types V and VI, and that use for hyperpigmentation other than facial melasma was not studied. It also contains pregnancy and other safety warnings.[source]
These statements identify evidence gaps and clinical decisions, not a reason to diagnose suitability from a comparison page. The prescriber should discuss relevant risks and the complete label.
A precise product with an individual dispensing cost
We did not verify one universal cash price. Ask the pharmacy for the prescribed quantity, current cost and applicable coverage, and keep the assessment fee separate.
The product review explains why a fixed triple combination differs from a custom cream with three ingredients. A matching ingredient count does not establish equivalence.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- DailyMed: current TRI-LUMA prescribing informationGalderma drug labeling; current accessible version checked October 8, 2026 · Checked October 8, 2026